Homan's sign is an important physical exam finding that can be used to identify deep vein thrombosis (DVT) and other vascular diseases. It is a sign of venous thrombosis in the lower limb that is characterized by pain and tenderness at the back of the calf when the foot is dorsiflexed. Despite its potential to provide valuable information in the diagnosis and treatment of DVT, Homan's sign is often overlooked in clinical practice. This article will explore the history and evidence behind Homan's sign, its potential for diagnosis and treatment, and the implications for clinical practice.
Homan's sign was first described by Dr. J.H. Homan in 1898 in a paper entitled "A Contribution to the Study of Thrombosis of the Veins of the Lower Extremity." In this paper, Dr. Homan described a sign of deep vein thrombosis in which pain and tenderness occurred at the back of the calf when the foot was dorsiflexed. He noted that this sign was often present in patients with DVT and that it could be used to differentiate DVT from other causes of calf pain. Since then, Homan's sign has become an important physical exam finding for the diagnosis of DVT.
Since the original description of Homan's sign, numerous studies have been conducted to evaluate its accuracy in the diagnosis of DVT. A systematic review of the literature found that the sensitivity of Homan's sign for the diagnosis of DVT ranged from 69% to 100%, with a pooled sensitivity of 87%. The specificity of Homan's sign was found to be between 62% and 100%, with a pooled specificity of 83%. These results indicate that Homan's sign is a useful tool for the diagnosis of DVT, although its accuracy is lower than that of other diagnostic tests such as duplex ultrasound.
Homan's sign can be used to diagnose DVT in patients who present with calf pain. It is important to note that Homan's sign is not diagnostic on its own, and should be used in conjunction with other tests such as duplex ultrasound. If Homan's sign is positive, further testing should be performed to confirm the diagnosis of DVT. Once a diagnosis of DVT has been confirmed, Homan's sign can be used to monitor the efficacy of treatment. If the patient's symptoms improve with treatment, Homan's sign should become negative. If the patient's symptoms persist despite treatment, Homan's sign should remain positive, indicating that further investigation and treatment is necessary.
Homan's sign is an important physical exam finding that can be used to diagnose and monitor the treatment of DVT. It is important for clinicians to be aware of this sign and to include it in their physical exam when evaluating patients with calf pain. In addition, clinicians should be aware that Homan's sign is not diagnostic on its own, and should therefore be used in conjunction with other tests such as duplex ultrasound to confirm the diagnosis of DVT.
Homan's sign is an important physical exam finding that can be used to diagnose and monitor the treatment of DVT. It is characterized by pain and tenderness at the back of the calf when the foot is dorsiflexed, and has a sensitivity of 87% and a specificity of 83%. Clinicians should be aware of this sign and include it in their physical exam when evaluating patients with calf pain. In addition, Homan's sign should be used in conjunction with other tests such as duplex ultrasound to confirm the diagnosis of DVT.
1.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
2.
According to new studies, some cancer patients can safely forego radiation therapy.
3.
According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.
4.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
5.
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
1.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
2.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
3.
Community-Based Cancer Survivorship Support Systems
4.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation